LabVantage Solutions, Somerset, NJ, has released the LabVantage covid-19 biobanking accelerator, a laboratory information management system (LIMS) purpose-built for covid-19. The solution enables laboratories to enter biospecimens into a biobank and rapidly begin conducting covid-19-related testing and research.
“Widespread laboratory testing is a critical component in the battle to control the coronavirus pandemic sweeping the globe,” says John Heiser, chief executive officer of LabVantage. “At LabVantage, we mobilized our decades of expertise to rapidly deliver a new purpose-built biobanking LIMS to support covid-19 testing and research. It incorporates our deep knowledge of biobanking along with numerous features designed to make it easy for laboratories to acquire, implement, and use the most powerful LIMS on the market for their covid-19 testing. The LIMS accelerator is also scalable, an important attribute as testing volumes escalate.”
The LabVantage covid-19 biobanking accelerator requires no infrastructure investment. Being preconfigured means minimal implementation time is needed, with a go-live start possible in less than 4 weeks. The system incorporates multiple protocols defined by the Centers for Disease Control and Prevention for covid-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification, and serology.
Customers pay an annual subscription fee to access the full LabVantage platform, which includes a biobanking solution, workflows and methods, consumables management, and Seagull barcode labeling software. The LabVantage covid-19 biobanking accelerator is available immediately.
For more information, visit LabVantage.
